The degree of RPL19 staining in cancer tissues was significantly higher than that in normal prostate tissues and benign prostatic hyperplasia tissues, and the survival time of patients with high RPL19 expression was shortened, suggesting that RPL19 could be used as a biomarker for the diagnosis and prognosis of prostate cancer. This evidence concerns the gene RPL19 and Familial prostate cancer.